Trials / Completed
CompletedNCT00637559
Barrett's Esophagus - 315 - 3 Way Cross-Over
A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole Magnesium |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2003-04-01
- Completion
- 2003-04-01
- First posted
- 2008-03-18
- Last updated
- 2011-01-25
Source: ClinicalTrials.gov record NCT00637559. Inclusion in this directory is not an endorsement.